RNS Number : 9112N

Gooch & Housego PLC

07 June 2022

7 June 2022


("G&H", the "Company" or the "Group")


Gooch & Housego PLC (AIM: GHH), the specialist manufacturer of optical components and systems, today announces its interim results for the six months ended 31 March 2022.

Key Financials

 Period ended 31 March           H1 2022    H1 2021     Change 
 Revenue                         GBP54.1m   GBP58.5m    (7.4)% 
                                ---------  ---------  ---------- 
 Adjusted profit before tax*     GBP3.6m    GBP4.9m     (26.6)% 
                                ---------  ---------  ---------- 
 Adjusted basic earnings per 
  share*                          11.8p      15.7p      (3.9p) 
                                ---------  ---------  ---------- 
 Net debt excluding IFRS 16      GBP5.9m    GBP4.7m     GBP1.2m 
                                ---------  ---------  ---------- 
 Net debt including IFRS 16      GBP12.0m   GBP12.1m   GBP(0.1)m 
                                ---------  ---------  ---------- 
 Statutory profit before tax     GBP1.2m    GBP0.7m      82.2% 
                                ---------  ---------  ---------- 
 Statutory basic earnings per 
  share                            6.9p       2.1p       4.8p 
                                ---------  ---------  ---------- 
 Interim dividend per share        4.7        4.5p       0.2p 
                                ---------  ---------  ---------- 

*Adjusted for amortisation of acquired intangible assets and non-recurring items.

Key points

-- Record order book at the half year end of GBP119.9m (31 March 2021: GBP92.8m), an increase of 29.2% or 25.6% at constant currency. H1 order intake was 1.42 times H1 revenue.

-- Strong and sustained demand in our main target markets. High demand for industrial lasers, in particular from semiconductors; G&H has increased market share in a growing market. Medical lasers continue to benefit from the return of elective surgery.

-- A&D affected by customer driven delays and new programmes not yet progressing to volume phase. Recent A&D order intake has been strong, including GBP4 million upgrade of optical imaging system for the UK MOD's Challenger upgrade programme.

-- Revenue has been constrained by pandemic related factors. COVID related staff absences impacted our US and UK sites and there were supply chain shortages. Substantial investment has been made to increase capacity and good progress has been made with recruitment of operators and securing our supply chain.

-- Adjusted profit before tax down due to lower volumes and investment in R&D and manufacturing capacity.

-- Group remains in a strong financial position. A new five year revolving credit facility ($40m committed/ $30m uncommitted) was put in place in March.

   --   Interim dividend of 4.7p per share (2021: 4.5p) reflecting positive outlook. 

-- Clear route to mid-teens returns in the near term through organic growth, internal investment and our well-established acquisition strategy.

Mark Webster , Chief Executive Officer of Gooch & Housego, commented:

"During the first half of the financial year there has been strong demand for the Group's technologies and capabilities and our order book has achieved another record level. However, in common with many industrial businesses, revenue was constrained by COVID related staff absences and supply chain disruption.

"We have made substantial investment to increase production capacity in areas where there has been strong demand, primarily through the hiring and training of new operators and building resilience within our supply chain. COVID cases have fallen markedly since the second quarter and absences have returned to normal levels. As a result we expect trading levels to accelerate in the second half.

"The Company remains committed to our long term strategic goals of diversification and moving up the value chain. We intend to vigorously pursue these goals through internal investment and where appropriate acquisitions.

"Full year expectations are unchanged and the long-term outlook for our technologies and capabilities in all our target sectors remains very strong."

Analyst meeting

A meeting for analysts will be held at 9.30am this morning, 7 June 2022 at the offices of Buchanan, 107 Cheapside, London EC2V 6DN. Analysts who require further details, please contact Buchanan at G&H@buchanan.uk.com .

A live audio webcast of the meeting will be available via the following link:


Following the meeting, a recording of the webcast will be made available for replay at the Group's website at https://gandh.com/investors/.

For further information please contact:

 Gooch & Housego PLC         Mark Webster / Chris Jewell     01460 256 440 
 Buchanan                    Mark Court / Sophie Wills       020 7466 5000 
 Investec Bank plc (Nomad 
  & Broker)                  Chris Baird / David Anderson    020 7597 5970 

Notes to editors

1 Gooch & Housego is a photonics technology business with operations in the USA, Europe and China. A world leader in its field, the company researches, designs, engineers and manufactures advanced photonic systems, components and instrumentation for applications in the Aerospace and Defence, Industrial and Telecom, Life Sciences and Scientific Research sectors. World leading design, development and manufacturing expertise is offered across a broad range of complementary technologies. It is headquartered in Ilminster, Somerset, UK.

2 . This announcement contains certain forward-looking statements that are based on management's current expectations or beliefs as well as assumptions about future events. These are subject to risk factors associated with, amongst other things, the economic and business circumstances occurring from time to time in the countries and sectors in which G&H operates. It is believed that the expectations reflected in these statements are reasonable but they may be affected by a wide range of variables which could cause actual results, and G&H's plans and objectives, to differ materially from those currently anticipated or implied in the forward-looking statements. Investors should not place undue reliance on any such statements. Nothing in this announcement should be construed as a profit forecast.

Operating and Financial Review

Performance Overview

Order intake for the six month period was 142% of revenue, compared with 109% of revenue for the second half of FY 2021, reflecting the accelerating growth in demand for our products and services. At 31 March 2022 our order book was at a record level of GBP119.9m (31 March 2021: GBP92.8m), an increase of 29.2%, or 25.6% at constant currency, compared with the same time last year.

In the first half of the financial year we have seen continued strong demand from our industrial laser and semiconductor markets. Demand for hi-reliability fibre couplers remains robust. In our Life Sciences markets demand for our medical laser products used extensively in cosmetic surgery has returned strongly, offsetting reductions in shipments for some of our medical diagnostic products that returned to good, but more normalised levels of demand post pandemic.

Our A&D revenues declined compared with the prior period. Whilst revenues to our commercial aerospace customers are starting to recover, we saw a number of customer-induced delays for our Boston site's programmes. Revenues in the first half were also impacted by reductions in demand for our optical arrays used on Unmanned Aerial Vehicle platforms as we completed deliveries on those programmes, whilst future expected ground vehicle programmes have not yet transitioned to the production delivery phase. Recent order intake for A&D has been strong, including a GBP4 million contract to upgrade optical systems on the UK MOD's Challenger tank upgrade programme.

In common with many businesses our output in the reported period was constrained as a result of COVID related absences both within our own teams and those of our suppliers. We have also been impacted to some degree by supply chain shortages especially for electronic components from Asia. COVID infection rates at our sites have fallen substantially since the end of the second quarter of the financial year and absence rates have now returned to normal levels.

Labour markets remain competitive in both US and UK and this has 'gated' the rate at which we have been able to add staff to service our growing order book. Real progress in the hiring and training of operators has been made in the first half of the financial year. There has been wage and material inflation across the period, but the Company is passing on those additional costs in the form of price increases across most of its portfolio.


 Six months ended 31 March       2022        2021 
                                 GBP'000    GBP'000   % Change 
---------------------------  -----------  ---------  --------- 
 Industrial                       27,743     26,570      4.4% 
 Aerospace & Defence              13,127     18,440     (28.8)% 
---------------------------  -----------  ---------  ------------ 
 Life Sciences                    13,264     13,450     (1.4)% 
---------------------------  -----------  ---------  ------------ 
 Group Revenue                    54,134     58,460     (7.4)% 
---------------------------  -----------  ---------  ------------ 

Products and Markets - Industrial

Gooch & Housego's principal industrial markets are industrial lasers, telecommunications, sensing and semiconductor manufacturing. Industrial lasers are used in a diverse range of precision material processing applications ranging from microelectronics and semiconductors to automotive manufacturing.

Overall, sales of products into our industrial markets in the six months to 31 March 2022 grew by 4.4%, or 4.7% when measured on a constant currency basis, compared with the equivalent period last year. We saw strong growth in industrial lasers, in particular for lasers used in the manufacture of semiconductors. Our revenues to these markets would have been even higher if we had been able to add productive capacity more quickly in our primary Acousto-Optic site and at our contract manufacturer's facility. Both were 'gated' by the hiring and training of new staff and good progress has been made in this regard across the first half of the financial year. We therefore anticipate a stronger performance in the second half. We expect demand levels especially from the semiconductor markets to remain strong.

High levels of COVID absences at our Czech sub contract partner used for the manufacture of typically 40% of our Hi-Rel fused fibre couplers constrained output in the first half of the financial year. Demand remains robust and a higher proportion than in the past of these fused fibre couplers are destined for space satellites which command a higher price and margin. We expect an improved performance in the second half.

Products and Markets - Aerospace & Defence (A&D)

Product quality, reliability and performance are paramount in this sector, playing to G&H's strengths, along with our commitment to provide value. We have solid, well established positions in target designation and range finding, ring laser and fibre optic gyroscope navigational systems, infrared and RF countermeasures, periscopes and sighting systems, opto-mechanical subsystems used in unmanned aerial vehicles (UAVs) and space satellite communications. We are working with our partners on the development of new directed energy weapon systems that are increasingly specified as part of the defensive suites of both naval and land platforms.

The trend in funding priorities in both the US and Europe continue to favour G&H products and capabilities. The need for all weather, precision guidance and targeting generates the demand for the product capabilities that G&H can offer. The current conflict in the Ukraine is also generating a recognition of the continuing importance of armoured vehicles in the modern military environment, and in that area G&H provides some of the most advanced optical sighting systems as evidenced by our recent receipt of a GBP4m order to support the UK MOD's programme to upgrade the Challenger MBT platform.

Despite the market trends supporting the longer-term growth of G&H's A&D business, revenue declined by 28.8% during the first six months of FY2022, compared with the equivalent period last year (28.9% constant currency). In the first half of FY2021 our Torquay business completed deliveries of laser communication systems to NEC/JAXA for use in their LUCAS (Laser Utilising Communication System) that demonstrated the viability of laser systems for high speed and scaleable space communication. Whilst this development revenue did not recur in the current half-year reporting period our work on the project provides the technology core for several significant tenders that we are currently submitting to customers for satellite based communication systems.

Our Boston business delivered lower revenue than the prior period principally as a result of customer induced programme delays. The impact of COVID isolation on our customers' ability to accept product shipments from our facility was significant and unavoidable given the need for their inspection sign off prior to our shipment. Despite the disappointing revenue performance of our Boston site in the period, its order book at the end of March 2022 was almost 50% higher than the equivalent period last year.

Encouragingly we are seeing recovery in demand from our commercial aerospace customers after the significant downturn during the pandemic. We are working to increase our productive capacity especially in our Moorpark, California facility this financial year. Our principal customers have indicated that they will consume the extra capacity as soon as it is brought on line.

Overall we expect a stronger second half and A&D remains an area of significant long term growth potential for G&H.

Products and Markets - Life Sciences

G&H's three principal Life Sciences revenue streams are derived from diagnostics applications (the design, development and manufacturing of diagnostic systems and fibre-optic modules based around our optical coherence tomography (OCT) technology), surgery / treatments (electro-optics and acousto-optics for medical lasers) and biomedical research (acousto-optics for microscopy applications).

Our Life Sciences / Biophotonics revenues were down 1.4% (reported and constant currency) in the six months to 31 March 2022, compared with the very strong prior period comparator. We have seen further recovery in demand for our components used in laser surgery, especially elective cosmetic surgery, which fell away during the pandemic. Offsetting this growth revenues from the sale of our medical diagnostic equipment, which had benefitted in particular from high demand for modules used in ventilator systems, were down compared with H1 2021. Demand for these units have returned to good, but more normal, pre-pandemic levels.

Our medical diagnostic design team based in our ITL business in Ashford have secured important orders for the development of our customers' next generation systems and these are expected to migrate to production over the coming two/three years. We are recruiting new software and mechanical design engineers to provide further capacity for additional customer development projects. Plans are also in place to invest in our ITL business in the US in order to provide a US based design and manufacturing offering to our customers in that market.


At Gooch & Housego we create sustainable value by leveraging our products and capabilities to diversify in to new markets. We are focussed on moving up the value chain, generating a greater portion of the Group's revenues from subassemblies and systems. We are delivering this strategy by focusing on three strategic priorities.

Focused R&D investment: In the first six months of the current financial year, G&H invested GBP4.1m in targeted R&D. This was a 4.7% increase on the same period last year demonstrating G&H's continued commitment to investing in targeted R&D programmes.

Our main investment areas are the next generation of precision lasers and laser systems, optical sensing for harsh environments, OCT medical diagnostics, laser surgery, space satellite communications, opto-mechanical systems for UAVs and armoured vehicles and direct energy systems. In the period the following projects made notable progress: key components for state of the art extreme ultra-violet lithography lasers used in the production of nano-electronics, market leading Germanium Acousto-Optic modulators for use in semiconductor manufacturing, thermal overlays of our traditional optical sighting systems for armoured vehicles and laser based satellite communications. Our R&D teams are working with our customers on the application of our existing Optical Coherence Tomography capabilities in to new cancer and cardio vascular disease detection applications.

We will continue to invest in novel, cutting edge technologies in order to drive future revenue growth across all of our target sectors.

Operational Excellence : our ambitious site rationalisation programme was completed in the reporting period. Final product line transfers from our Baltimore facility to our Boston facility were finalised and our production teams in Boston are now servicing those products from within the existing Boston manufacturing footprint. Likewise our Precision Optics centre of excellence in Ilminster is now manufacturing product transferred from our St Asaph production facility, liaising closely and effectively with the optical systems design team that have been retained in a new facility in St Asaph.

As previously reported the transfer of production of our established acousto-optic products from Ilminster to our Asian contract manufacturing partner is complete. Their initial ramp up to volume manufacture of our products has been completed and we are now supporting them to achieve yet greater volumes to help service the very significant demand we are seeing for our acousto-optic products. To that end we have located our own supply chain, quality and engineering staff permanently in their production facility.

Following the successful transfer of many of our acousto-optic products to our contract manufacturing partner we are also working to establish them as a further supply source for our hi-rel fibre couplers. In time they will become a third source for these products supplementing our own in-house production as well as that of our existing European supplier. The production transfer is progressing well and our contract manufacturing partner is currently completing the qualification of their production lines against the very demanding criteria set by our customers. We expect our partner to contribute to G&H supply of these products from early FY2023.

We will continue to review our higher volume, established products with a view to transferring them to our contract manufacturing partner. Our UK and US sites will focus on newer, innovative products that require higher local input from our engineering team.

Revenue in the first half of the financial year has been constrained by pandemic factors. COVID related absences have impacted our production sites in the UK and US and key suppliers during the period. A competitive labour market in the UK and US has been a 'gating' factor on increasing capacity. COVID related absences have declined since the middle of the second quarter. During the first half good progress has been made hiring and training new operators. We expect these measures to result in increased output in the second half of the financial year and an improved performance.

From the beginning of this financial year we have invested additional resources in to our supply chain team including quality engineers who undertake a programme of physical visits to our suppliers' facilities to ensure they adhere to the product specification and quality levels that we demand of them. They also explore with our suppliers potential cost reduction opportunities. Whilst our supply chain has in general experienced some disruption from COVID absences and cost input inflation the relationships we have established with them put us in a good position to meet the our goal of maintaining continuity of supply in the current challenging market conditions.

Value enhancing acquisitions

G&H continues to evaluate acquisition opportunities that have the potential to accelerate delivery of the Company's strategic objectives. Having established a presence in its target markets, G&H remains focused on moving up the value chain in each of those markets. We have a clearly defined set of criteria against which we assess potential acquisition targets. Our focus areas continue to be in the markets of Life Sciences and Aerospace & Defence although we also consider acquisition targets in the Industrial market space if they have particular technologies that are attractive to us.

During the period we have had a number of discussions with the management teams of target companies to better assess their suitability to become part of the G&H Group and the synergistic opportunities that would result. We remain optimistic that these conversations will result in the addition of new businesses to the Group in the near future. The Group has a strong balance sheet and access to significant debt facilities meaning we are in a strong position to execute on transactions quickly.

Diversification: The recent pandemic demonstrated the success of G&H's strategy of balancing the business more evenly between its three markets offering natural protection against cyclicality in any particular sector. During the pandemic when our Industrial and Commercial Aerospace markets declined, our presence in Life Sciences and Defence markets helped to offset the overall impact on Group revenues. In the current financial year we are seeing very strong recovery in our Industrial and Medical Laser markets which now offset a temporary programmatic reduction in our Defence revenues as well as the return to more normal demand levels for our medical diagnostic equipment. We will continue to look to acquisitions to help us further diversify the business and support the long-term sustainable growth of the business.

Moving up the Value Chain: We continue to use our research and development resources to help us secure a greater proportion of our business from sub-assemblies and systems further supporting our transition from being a component supplier to a solutions provider. For example by combining the firmware capabilities of our optical systems design team in St Asaph with the electronics and software skills of our Ashford engineering team we are able to offer next generation multi-band sights incorporating laser range finding and advanced image overlay for use in next generation optical systems for military vehicles. Our continuing investments in state of the art equipment to manufacture and coat precision optics mean that we are able to offer our customers an expanded range of services and in turn we are being invited to tender for more complex, innovative optical assemblies by both existing and new customers.

Principal Risks and Uncertainties

The principal risks and uncertainties to which the Group is exposed and our approach to managing those risks are unchanged from those identified on page 47 of our 2021 Annual Report. Whilst the risk to the business from the pandemic appears to be abating and COVID related absences in our facilities reduce, we remain alert to the impact of potential further disruption arising from new variants of the virus.

The post pandemic recovery in many of our markets has resulted in increased demand for skilled employees resulting in competitive labour markets in both the UK and US. In order to retain and attract employees we have increased levels of pay for some skill groups beyond the general company-wide salary awards made to our staff at the beginning of the calendar year.

Employment pressures have also impacted our suppliers who seek to pass on wage inflation in their supply prices to G&H. In some cases pandemic related absences have also meant they have been unable to supply to us. We take measures to protect ourselves from these risks by maintaining buffer stocks of key components where necessary although these are not always sufficient protection in the case of protracted delays. Our supply chain teams also seek to put in place long-term agreements with our suppliers which help to lock in pricing for longer and provide some near term protection against inflationary pressures.

In the medium term our supply chain teams work with our engineering team to identify and qualify alternative sources of supply to mitigate the risk from sole source suppliers. In general, we are able to pass on cost inflation to our customers in the form of higher prices.

The situation in the Ukraine has not had a material impact on the Group which had very limited exposure to customers and suppliers in Russia and the Ukraine prior to the conflict. The enhanced sanctions regime implemented by UK Government has had no impact on G&H.

Alternative Performance Measures

In the analysis of the Group's financial performance alternative performance measures are presented to provide readers with additional information. The interim report includes both statutory and adjusted non-GAAP financial measures, the latter of which the Directors believe better reflect the underlying performance of the business. Items excluded from the adjusted results, together with their prior period comparatives, are set out below.

Reconciliation of adjusted performance measures

                    Operating       Net finance      Profit before      Taxation        Profit after       Earnings 
                      profit           costs              tax                                tax           per share 
---------------                   ---------------  ----------------  ---------------  ----------------  -------------- 
 Half Year to     2022    2021     2022    2021      2022     2021    2022    2021     2022     2021     2022    2021 
 31              GBP000   GBP000  GBP000   GBP000   GBP000   GBP000  GBP000   GBP000   GBP000   GBP000   pence   pence 
---------------  ------  -------  ------  -------  -------  -------  ------  -------  -------  -------  ------  ------ 
 Reported         1,574    1,175   (353)    (505)    1,221      670     504    (132)    1,725      538     6.9     2.1 
---------------  ------  -------  ------  -------  -------  -------  ------  -------  -------  -------  ------  ------ 
  assets            927    1,091       -        -      927    1,091   (217)    (214)      710      877     2.8     3.5 
  costs           1,445    3,134       -        -    1,445    3,134   (252)    (615)    1,193    2,519     4.8    10.1 
 Deferred tax 
  goodwill            -        -       -        -        -        -   (675)        -    (675)        -   (2.7)       - 
 Adjusted         3,946    5,400   (353)    (505)    3,593    4,895   (640)    (961)    2,953    3,934    11.8    15.7 
---------------  ------  -------  ------  -------  -------  -------  ------  -------  -------  -------  ------  ------ 

Adjusted profit before tax was GBP3.6m, a decrease of 26.6% on the prior year (H1 2021: GBP4.9m). This reduction in profit reflects lower revenues as a result of the constraining effects on the Group's output of COVID absences both in house and within our supply chain and other pandemic effects.

Cash Flow and Financing

In the six months ended 31 March 2022, G&H generated cash from operations of GBP3.2m, compared with GBP9.7m in the same period of 2021. A strategic investment of GBP3.3m was made in inventory to support the ramp up of output expected in the second half of the year in response to record order book levels. There was a net inflow of GBP0.1m from the movement on receivables and payables.

Capital expenditure on property, plant and equipment was GBP3.0m in the period (2021: GBP3.3m). Further investments have been made at our Ilminster facility for advanced measuring systems to help achieve the very tight tolerances required by our customers of the precision optics supplied to them. We have also invested in our Boston site to reconfigure the production areas to integrate the production lines previously located at our Baltimore facility. In the period we invested in a new Customer Relationship Management system to assist our sales team in the efficient pursuit of new orders.

On 31 March 2022 the Group entered in to a new $40m five year term revolving credit facility with a further $30m flexible acquisition facility available to support the Group's acquisition strategy. At the end of March the balance drawn on the revolving credit facility was $19.6m (September 2021: $14.8m).

At 31 March 2022 the Group's net debt totalled GBP12.0m (30 September 2021 - GBP9.2m) including lease liabilities of GBP6.1m (30 September 2021 - GBP6.6m). Consistent with the Group's borrowing agreements, which exclude the impact of IFRS 16, Leases, our leverage ratio was 0.3 times at 31 March 2022 (31 March 2021: 0.3 times).

Environmental, Social and Governance

During the reporting period we have finalised the installation of new solar photo-voltaic energy generation systems at both our Ilminster and Ashford facilities. These two systems have the capacity to generate approximately 450 kWp, adding to the self-generated electricity that our Torquay site's solar panels have provided for the last few years. We have also developed plans for each of our sites to reduce the energy they consume supporting this through additional capital expenditure where necessary. In the first half of the year the Group's greenhouse gas emissions reduced by 32.3% compared with the comparator period thanks to our site consolidation programme and the sourcing of 100% of our purchased electricity in the UK from renewables sources.

In order to strengthen the linkage between the Board and the wider workforce Jim Haynes, one of our non-executive directors, was appointed as the director with responsibility for workforce engagement. Jim has held a number of sessions with employee representative groups at our sites and feedback from those sessions is addressed. It is pleasing to note that our employees recognised and appreciated the support measures put in place by the Group during the pandemic. It is also clear that many office-based staff enjoy the greater flexibility given to them for home working which the Group is keen to support where appropriate to their particular role.

We are delighted to be offering additional apprenticeship roles at our Precision Optics centre in Ilminster. These apprentices will be working in our centre's production areas and will be trained to set up and operate our state of the art precision optics cutting, polishing and coating equipment. We look forward to them taking their place in a few years' time within our production management teams.


Given the positive outlook for the Group, the Board has declared an interim dividend of 4.7 p per share (2021: 4.5p). This dividend will be payable to shareholders on the register as at 24 June 2022 on 29 July 2022.

Prospects and outlook

There is strong and sustained demand across the Company's target markets and our order book stands at a record level. The order book includes significant new programme wins for next generation products in the field of acousto-optic modulators, electronic optical sighting systems and medical lasers. The growth in the order book has continued since the half year. We have invested in substantial additional capacity, in particular at our site in Fremont, CA which services the semiconductor market, Cleveland, OH which services the medical laser market and Ilminster, Somerset which services the A&D optics market. These are the areas where growth in order book demand has been the most significant. Absence levels in our facilities have returned to normal levels and output levels are increasing as a result of the investment made in the first half of the year.

We continue to invest in our highly productive R&D team. Our engineering resources are focused on working with our customers on their next generation development programmes. There are a number of near term opportunities which include developing the next generation of extreme ultra violet lasers for the manufacture of nanoelectronics; using our laser based satellite communication technology in new constellation satellite systems and exploiting our optical coherence tomography capability in cardiovascular disease detection. The establishment of our UK precision optics centre of excellence in Ilminster is resulting in awards for new, more complex optical assembly work providing us with more valuable and longer-term revenue opportunities.

We have entered in to a new five-year debt facility. Our balance sheet is robust, with low net debt and we are in a good position to continue to invest in our target sectors. The Board's confidence in the trading prospects of the Group are reflected in an increased interim dividend for the year.

The Company remains committed to our long term strategic goals of diversification and moving up the value chain. We intend to vigorously pursue these goals through internal investment and where appropriate, acquisitions.

Full year expectations are unchanged and the long-term outlook for our technologies and capabilities in all our target sectors remains very strong. We have a clear route to mid teens returns through organic growth, internal investment and our well-established acquisition strategy.

   Mark Webster                        Chris Jewell 
   Chief Executive Officer         Chief Financial Officer 

7 June 2022

Group Income Statement

Unaudited interim results for the 6 months ended 31 March 2022

                          Half Year to 31 March                 Half Year to 31 March                 Full Year 
                           2022 (Unaudited)                      2021 (Unaudited)                      to 30 September 
                                                                                                       2021 (Audited) 
                    Note  Underlying  Non-underlying   Total    Underlying  Non-underlying   Total         Total 
                           GBP'000       GBP'000      GBP'000    GBP'000       GBP'000      GBP'000       GBP'000 
Revenue             4         54,134               -    54,134      58,460               -    58,460           124,074 
Cost of revenue             (36,791)               -  (36,791)    (39,575)               -  (39,575)          (82,753) 
                          ----------  --------------  --------  ----------  --------------  --------  ---------------- 
Gross profit                  17,343               -    17,343      18,885               -    18,885            41,321 
Research and 
 development                 (4,118)               -   (4,118)     (3,933)               -   (3,933)           (8,147) 
Sales and 
 marketing                   (3,994)               -   (3,994)     (3,962)               -   (3,962)           (8,342) 
Administration               (5,554)         (2,372)   (7,926)     (6,169)         (4,225)  (10,394)          (20,235) 
Other income 
 and expenses                    269               -       269         579               -       579               804 
                          ----------  --------------  --------  ----------  --------------  --------  ---------------- 
Operating profit    4          3,946         (2,372)     1,574       5,400         (4,225)     1,175             5,401 
Net finance 
 costs                         (353)               -     (353)       (505)               -     (505)             (721) 
                          ----------  --------------  --------  ----------  --------------  --------  ---------------- 
Profit before 
 income tax 
 expense                       3,593         (2,372)     1,221       4,895         (4,225)       670             4,680 
Income tax 
 expense            6          (640)           1,144       504       (961)             829     (132)           (1,276) 
                          ----------  --------------  --------  ----------  --------------  --------  ---------------- 
Profit for 
 the year                      2,953         (1,228)     1,725       3,934         (3,396)       538             3,404 
                          ----------  --------------  --------  ----------  --------------  --------  ---------------- 
Basic earnings 
 per share          7          11.8p          (4.9p)      6.9p       15.7p         (13.6p)      2.1p             13.6p 
Diluted earnings 
 per share           7         11.7p          (4.8p)      6.9p       15.6p         (13.5p)      2.1p             13.5p 
                          ----------  --------------  --------  ----------  --------------  --------  ---------------- 

Group Statement of Comprehensive Income

                                       Half Year       Half Year       Full Year 
                                           to              to              to 
                                         31 Mar        31 Mar 2021     30 Sep 2021 
                                       (Unaudited)     (Unaudited)      (Audited) 
                                        GBP'000         GBP'000         GBP'000 
                                    --------------  --------------  -------------- 
 Profit for the period                       1,725             538           3,404 
 Other comprehensive (expense) 
  / income 
 (Losses) / gains on cash flow 
  hedges                                      (33)              59           (468) 
 Currency translation differences            1,104         (2,890)         (1,621) 
                                    --------------  --------------  -------------- 
 Other comprehensive income / 
  (expense) for the period                   1,071         (2,831)         (2,089) 
 Total comprehensive income / 
  (expense) for the period                   2,796         (2,293)           1,315 
                                    --------------  --------------  -------------- 

Group Balance Sheet

Unaudited interim results for the 6 months ended 31 March 2022

                                          31 Mar 2022     31 Mar 2021    30 Sep 2021 
                                           (Unaudited)     (Unaudited)     (Audited) 
                                            GBP'000         GBP'000        GBP'000 
                                        --------------  --------------  ------------ 
 Non-current assets 
 Property, plant and equipment                  38,446          38,354        37,945 
 Right of use assets                             4,908           6,064         5,230 
 Intangible assets                              51,098          51,572        50,835 
 Deferred tax assets                             1,861           1,466         1,883 
                                        --------------  --------------  ------------ 
                                                96,313          97,456        95,893 
 Current assets 
 Inventories                                    31,816          28,226        28,150 
 Trade and other receivables                    24,466          23,861        28,310 
 Cash and cash equivalents                       8,951          15,286         8,352 
                                                65,233          67,373        64,812 
 Current liabilities 
 Trade and other payables                     (15,618)        (17,704)      (19,324) 
 Borrowings                                       (66)            (64)          (65) 
 Lease liabilities                             (1,485)         (1,647)       (1,588) 
 Tax liabilities                               (1,229)           (282)         (481) 
                                              (18,398)        (19,697)      (21,458) 
 Net current assets                             46,835          47,676        43,354 
                                        --------------  --------------  ------------ 
 Non-current liabilities 
 Borrowings                                   (14,813)        (19,951)      (10,903) 
 Lease liabilities                             (4,575)         (5,684)       (5,039) 
 Provision for other liabilities 
  and charges                                  (1,444)         (1,705)       (1,447) 
 Deferred tax liabilities                      (7,132)         (6,376)       (7,582) 
                                              (27,964)        (33,716)      (24,971) 
 Net assets                                    115,184         111,416       114,276 
                                        --------------  --------------  ------------ 
 Shareholders' equity 
 Called up share capital                         5,008           5,008         5,008 
 Share premium account                          16,000          16,000        16,000 
 Merger reserve                                  7,262           7,262         7,262 
 Cumulative translation reserve                  7,158           4,785         6,054 
 Hedging reserve                                 (168)             392         (135) 
 Retained earnings                              79,924          77,969        80,087 
                                        --------------  --------------  ------------ 
 Equity Shareholders' Funds                    115,184         111,416       114,276 
                                        --------------  --------------  ------------ 

Statement of Changes in Equity

Unaudited interim results for the 6 months ended 31 March 2022

                                Share     Share     Merger   Retained   Hedging    Cumulative    Total 
                                capital   premium   reserve   earnings   reserve   translation   equity 
                                account   account                                    reserve 
                               --------  --------  --------  ---------  --------  ------------  ------- 
                                GBP000    GBP000    GBP000    GBP000     GBP000      GBP000     GBP000 
At 1 October 2020                 5,008    16,000     7,262     77,075       333         7,675  113,353 
Profit for the period                 -         -         -        538         -             -      538 
Other comprehensive 
 expense for the period               -         -         -          -        59       (2,890)  (2,831) 
                               --------  --------  --------  ---------  --------  ------------  ------- 
Total comprehensive 
 income / (expense) 
 for the period                       -         -         -        538        59       (2,890)  (2,293) 
                               --------  --------  --------  ---------  --------  ------------  ------- 
Share based payments                  -         -         -        356         -             -      356 
At 31 March 2021 (unaudited)      5,008    16,000     7,262     77,969       392         4,785  111,416 
                               --------  --------  --------  ---------  --------  ------------  ------- 
At 1 October 2021                 5,008    16,000     7,262     80,087     (135)         6,054  114,276 
Profit for the period                 -         -         -      1,725         -             -    1,725 
Other comprehensive 
 (expense) / income 
 for the period                       -         -         -          -      (33)         1,104    1,071 
                               --------  --------  --------  ---------  --------  ------------  ------- 
Total comprehensive 
 income / (expense) 
 for the period                       -         -         -      1,725      (33)         1,104    2,976 
                               --------  --------  --------  ---------  --------  ------------  ------- 
Dividends                                                      (1,928)                          (1,928) 
Share based payments                  -         -         -         40         -             -       40 
At 31 March 2022 (unaudited)      5,008    16,000     7,262     79,924     (168)         7,158  115,184 
                               --------  --------  --------  ---------  --------  ------------  ------- 

Group Cash Flow Statement

Unaudited interim results for the 6 months ended 31 March 2022

                                                  Half Year           Half Year          Full Year 
                                                  to 31 Mar           to 31 Mar          to 30 Sep 
                                               2022 (Unaudited)    2021 (Unaudited)    2021 (Audited) 
                                                   GBP'000             GBP'000            GBP'000 
                                             ------------------  ------------------  ---------------- 
 Cash flows from operating activities 
 Cash generated from operations                           3,216               9,720            16,822 
 Income tax refunded / (paid)                               823               (476)             (575) 
                                             ------------------  ------------------  ---------------- 
 Net cash generated from operating 
  activities                                              4,039               9,244            16,247 
                                             ------------------  ------------------  ---------------- 
 Cash flows from investing activities 
 Acquisition of subsidiaries, net 
  of cash acquired                                            -             (3,250)           (3,250) 
 Purchase of property, plant and equipment              (3,004)             (3,340)           (5,399) 
 Sale of property, plant and equipment                        3                   -                38 
 Purchase of intangible assets                            (966)               (524)             (844) 
 Interest received                                            2                   1                 1 
 Interest paid                                            (295)               (465)             (505) 
 Net cash used in investing activities                  (4,260)             (7,578)           (9,959) 
                                             ------------------  ------------------  ---------------- 
 Cash flows from financing activities 
 Drawdown of borrowings                                   4,258                   -                 - 
 Repayment of borrowings                                  (758)             (4,736)          (14,093) 
 Repayment of lease liabilities                           (796)               (899)           (2,047) 
 Dividends paid to ordinary shareholders                (1,928)                   -           (1,127) 
 Net cash generated by / (used in) 
  financing activities                                      776             (5,635)          (17,267) 
                                             ------------------  ------------------  ---------------- 
 Net increase/ (decrease) in cash                           555             (3,969)          (10,979) 
 Cash at beginning of the period                          8,352              19,734            19,734 
 Exchange gains / (losses) gains on 
  cash                                                       44               (479)             (403) 
                                             ------------------  ------------------  ---------------- 
 Cash at the end of the period                            8,951              15,286             8,352 
                                             ------------------  ------------------  ---------------- 

Notes to the Group Cash Flow Statement

                                            Half Year           Half Year          Full Year 
                                            to 31 Mar           to 31 Mar          to 30 Sep 
                                         2022 (Unaudited)    2021 (Unaudited)    2021 (Audited) 
                                             GBP'000             GBP'000            GBP'000 
 Profit before income tax                           1,221                 670             4,680 
 Adjustments for: 
 - Amortisation of acquired 
  intangible assets                                   927               1,091             2,081 
 - Amortisation of other intangible 
  assets                                              593                 567             1,275 
 - Loss on disposal of property, 
  plant and equipment                                  12                   -                95 
 - Depreciation                                     3,396               3,282             7,030 
 - Share based payments                                40                 356               735 
 - Amounts claimed under the 
  RDEC                                              (113)               (174)             (280) 
 - Finance income                                     (2)                 (1)               (1) 
 - Finance costs                                      355                 506               722 
                                       ------------------  ------------------  ---------------- 
 Total adjustments                                  5,208               5,627            11,657 
 Changes in working capital 
 - Inventories                                    (3,294)               1,528             1,888 
 - Trade and other receivables                      4,427               1,676           (2,655) 
 - Trade and other payables                       (4,346)                 219             1,252 
 Total changes in working capital                 (3,213)               3,423               485 
 Cash generated from operating 
  activities                                        3,216               9,720            16,822 
                                       ------------------  ------------------  ---------------- 

Reconciliation of net cash flow to movements in net debt

                                          Half Year     Half Year to     Full Year 
                                              to                         to 30 Sep 
                                          31 Mar 2022     31 Mar 2021     (Audited) 
                                          (Unaudited)     (Unaudited) 
                                           GBP'000         GBP'000        GBP'000 
                                       --------------  --------------  ------------ 
 Increase / (decrease) in cash 
  in the period                                   555         (3,969)      (10,979) 
 Drawdown of borrowings                       (4,258)               -             - 
 Repayment of borrowings                        1,678           5,635        16,140 
 Changes in net debt resulting 
  from cash flows                             (2,025)           1,666         5,161 
 New leases                                      (12)           (503)         (510) 
 Non cash movements                             (261)             (8)         (393) 
 Translation differences                        (447)           1,522         1,236 
                                       --------------  --------------  ------------ 
 Movement in net debt in the 
  period / year                               (2,745)           2,677         5,494 
 Net debt at start of period                  (9,243)        (14,737)      (14,737) 
 Net debt at end of period                   (11,988)        (12,060)       (9,243) 
                                       --------------  --------------  ------------ 

Analysis of net debt

                        At 1 Oct   New leases   Cash flow   Exchange    Non-cash     At 31 
                          2021                               movement    movement      Mar 
                        GBP'000     GBP'000      GBP'000     GBP'000     GBP'000    GBP'000 
                       ---------  -----------  ----------  ----------  ----------  --------- 
 Cash at bank and 
  in hand                  8,352            -         555          44           -      8,951 
 Due within one year 
 Debt                       (65)            -          32           -        (33)       (66) 
 Lease liabilities       (1,588)          (4)         920        (18)       (795)    (1,485) 
 Due after one year 
 Debt                   (10,903)            -     (3,532)       (350)        (28)   (14,813) 
 Lease liabilities       (5,039)          (8)           -       (123)         595    (4,575) 
 Net debt                (9,243)         (12)     (2,025)       (447)       (261)   (11,988) 
                       ---------  -----------  ----------  ----------  ----------  --------- 

Notes to the Interim Report

   1.     Basis of Preparation 

The unaudited Interim Report has been prepared under the historical cost convention and in accordance with International Financial Reporting Standards ("IFRS"), as adopted by the European Union.

The Group remains significantly within its debt facility covenants and is forecasting to be cash generative in the second half of the financial year. These cash flow projections show that the Group has sufficient funding available to withstand plausible downside scenarios, and therefore the financial statements have been prepared on a going concern basis.

The Interim Report was approved by the Board of Directors and the Audit Committee on 7 June 2022. The Interim Report does not constitute statutory financial statements within the meaning of the Companies Act 2006 and has not been audited.

Comparative figures in the Interim Report for the year ended 30 September 2021 have been taken from the Group's audited statutory financial statements on which the Group's auditors, PricewaterhouseCoopers LLP, expressed an unqualified opinion. The comparative figures to 31 March 2021 are unaudited.

The Interim Report will be announced to all shareholders on the London Stock Exchange and published on the Group's website on 7 June 2022. Copies will be available to members of the public upon application to the Company Secretary at Dowlish Ford, Ilminster, Somerset, TA19 0PF.

The accounting policies adopted are consistent with those of the annual financial statements for the year ended 30 September 2021, as described in those financial statements.

   2.     Estimates 

The preparation of interim financial statements requires management to make estimates and assumptions that affect the application of accounting policies and the reported amounts of assets and liabilities, income and expense. Actual results may differ from these estimates.

In preparing these condensed consolidated interim financial statements, the significant judgments made by management in applying the Company's accounting policies and the key sources of estimation uncertainty were the same as those that applied to the consolidated financial statements for the year ended 30 September 2021.

   3.     Financial risk management 

The Company's activities expose it to a variety of financial risks, market risk (including currency risk, cash flow interest rate risk and price risk), credit risk and liquidity risk.

The interim condensed consolidated financial statements do not include all financial risk management information and disclosures required in the annual financial statements and should be read in conjunction with the Company's annual financial statements as at 30 September 2021. There have been no changes to the risk management policies since the year end.

   4.     Segmental analysis 
                                Aerospace    Life Sciences   Industrial  Corporate   Total 
                                 & Defence   / Biophotonics 
For half year to 31 March        GBP'000        GBP'000       GBP'000     GBP'000   GBP'000 
Total revenue                       14,554           14,964      30,206          -    59,724 
Inter and intra-division           (1,427)          (1,700)     (2,463)          -   (5,590) 
------------------------------  ----------  ---------------  ----------  ---------  -------- 
External revenue                    13,127           13,264      27,743          -    54,134 
Divisional expenses               (14,603)         (10,569)    (22,937)        465  (47,644) 
------------------------------  ----------  ---------------  ----------  ---------  -------- 
EBITDA(1)                          (1,476)            2,695       4,806        465     6,490 
EBITDA %                           (11.2)%            20.3%       17.3%          -     12.0% 
Depreciation and amortisation      (1,234)            (784)     (1,457)      (514)   (3,989) 
------------------------------  ----------  ---------------  ----------  ---------  -------- 
Operating profit before 
 amortisation of acquired 
 intangible assets                 (2,710)            1,911       3,349       (49)     2,501 
Amortisation of acquired 
 intangible assets                       -                -           -      (927)     (927) 
------------------------------  ----------  ---------------  ----------  ---------  -------- 
Operating profit                   (2,710)            1,911       3,349      (976)     1,574 
Operating profit margin 
 %                                 (20.6)%            14.4%       12.1%          -      2.9% 
------------------------------  ----------  ---------------  ----------  ---------  -------- 
Add back non-recurring 
 items                                 469              188         788        927     2,372 
Operating profit excluding 
 non-recurring items               (2,241)            2,099       4,137       (49)     3,946 
------------------------------  ----------  ---------------  ----------  ---------  -------- 
Adjusted operating profit 
 margin %                          (17.1)%            15.8%       14.9%          -      7.3% 
------------------------------  ----------  ---------------  ----------  ---------  -------- 
                                Aerospace    Life Sciences   Industrial  Corporate   Total 
                                 & Defence   / Biophotonics 
For half year to 31 March        GBP'000        GBP'000       GBP'000     GBP'000   GBP'000 
Total revenue                       18,440           14,742      30,519          -    63,701 
Inter and intra-division                 -          (1,292)     (3,949)          -   (5,241) 
------------------------------  ----------  ---------------  ----------  ---------  -------- 
External revenue                    18,440           13,450      26,570          -    58,460 
Divisional expenses               (18,466)         (10,694)    (23,618)        433  (52,345) 
------------------------------  ----------  ---------------  ----------  ---------  -------- 
EBITDA(1)                             (26)            2,756       2,952        433     6,115 
EBITDA %                                 -            20.5%       11.1%          -     10.5% 
Depreciation and amortisation      (1,284)            (652)     (1,199)      (714)   (3,849) 
------------------------------  ----------  ---------------  ----------  ---------  -------- 
Operating profit before 
 amortisation of acquired 
 intangible assets                 (1,310)            2,104       1,753      (281)     2,266 
Amortisation of acquired 
 intangible assets                       -                -           -    (1,091)   (1,091) 
------------------------------  ----------  ---------------  ----------  ---------  -------- 
Operating profit                   (1,310)            2,104       1,753    (1,372)     1,175 
Operating profit margin 
 %                                  (7.1%)            15.6%        6.6%          -      2.0% 
------------------------------  ----------  ---------------  ----------  ---------  -------- 
Add back non-recurring 
 items                               1,503              435       1,196      1,091     4,225 
Operating profit excluding 
 non-recurring items                   193            2,539       2,949      (281)     5,400 
------------------------------  ----------  ---------------  ----------  ---------  -------- 
 Adjusted operating profit 
  margin %                            1.0%            18.9%       11.1%          -      9.2% 
------------------------------  ----------  ---------------  ----------  ---------  -------- 

(1)EBITDA = Earnings before interest, tax, depreciation and amortisation.

All of the amounts recorded are in respect of continuing operations.

   4.     Segmental analysis continued 

Analysis of revenue by destination

                             Half year          Half year 
                                 to                 to 
                             31 Mar 2022        31 Mar 2021 
                             (Unaudited)        (Unaudited) 
                              GBP'000            GBP'000 
                           -------------      ------------- 
 United Kingdom                   13,267             15,008 
 North and South America          19,224             23,093 
 Continental Europe               11,910              9,159 
 Asia-Pacific                      9,733             11,200 
                                  54,134             58,460 
                           -------------      ------------- 
   5.     Non-recurring items 
                                               Half Year       Half Year       Full Year 
                                                   to              to              to 
                                               31 Mar 2022     31 Mar 2021     30 Sep 2021 
                                               (Unaudited)     (Unaudited)      (Audited) 
                                                GBP'000         GBP'000         GBP'000 
                                            --------------  --------------  -------------- 
 Profit before tax                                   1,221             670           4,680 
 Amortisation of acquired intangible 
  assets                                               927           1,091           2,081 
 Restructuring costs                                 1,445           3,134           5,860 
 Adjusted profit before tax                          3,593           4,895          12,621 
                                            --------------  --------------  -------------- 

The restructuring costs in the period ended 31 March 2022 relate to non-recurring costs arising from our manufacturing streamlining activities, further detail of which is given in the Operating and Financial Review.

   6.     Tax expense 

Analysis of tax charge in the period

                                                 Half Year       Half Year        Full Year 
                                                     to              to           to 30 Sep 
                                                                                2021 (Audited) 
                                                31 Mar 2022        31 Mar 
                                                 (Unaudited)     (Unaudited) 
                                                  GBP'000         GBP'000          GBP'000 
 Current taxation 
 UK Corporation tax                                      356           (105)               722 
 Overseas tax                                          (100)            (79)               292 
 Adjustments in respect of prior 
  year tax charge                                      (250)               -             (807) 
 Total current tax                                         6           (184)               207 
 Deferred tax 
 Origination and reversal of temporary 
  differences                                          (118)             316                 1 
 Adjustments in respect of prior 
  years                                                (392)               -               549 
 Change to UK tax rate                                     -               -               519 
 Total deferred tax                                    (510)             316             1,069 
 Tax expense per income statement                        504             132             1,276 

The tax charge for the six months ended 31 March 2022 is based on the estimated effective rate of the tax for the Group for the full year to 30 September 2022. The estimated rate is applied to the profit before tax.

The adjusted effective tax rate is 17.8% (H1 2021: 19.6%).

   7.     Earnings per share 

The calculation of earnings per 20p Ordinary Share is based on the profit for the period using as a divisor the weighted average number of Ordinary Shares in issue during the period. The weighted average number of shares is given below.

                                         Half Year       Half Year      Full Year 
                                             to              to         to 30 Sep 
                                         31 Mar 2021     31 Mar 2021     (Audited) 
                                         (Unaudited)     (Unaudited) 
                                            No.             No.            No. 
                                      --------------  --------------  ------------ 
 Number of shares used for basic 
  earnings per share                      25,040,919      25,040,919    25,040,919 
 Dilutive shares                             127,937         195,624       239,603 
 Number of shares used for dilutive 
  earnings per share                      25,168,856      25,236,543    25,280,522 
                                      --------------  --------------  ------------ 

A reconciliation of the earnings used in the earnings per share calculation is set out below:

                                          Half Year to       Half Year to       Full Year to 
                                           31 Mar 2022        31 Mar 2021        30 Sep 2021 
                                                              (Unaudited)         (Audited) 
                                                   p per              p per              p per 
                                        GBP'000    share   GBP'000    share   GBP'000    share 
                                       --------  -------  --------  -------  --------  ------- 
 Basic earnings per share                 1,725     6.9p       538     2.1p     3,404    13.6p 
 Adjustments net of income 
  tax expense: 
 Amortisation of acquired intangible 
  assets                                    710     2.8p       877     3.5p     1,621     6.5p 
 Restructuring costs                      1,193     4.8p     2,519    10.1p     4,709    18.8p 
 Adjustment to deferred tax 
  on goodwill                             (675)   (2.7p)         -        -         -        - 
 Restatement of UK deferred 
  tax                                         -        -         -        -       519     2.1p 
 Total adjustments net of 
  income tax expense                      1,228     4.9p     3,396    13.6p     6,849    27.4p 
 Adjusted basic earnings per 
  share                                   2,953    11.8p     3,934    15.7p    10,253    41.0p 
                                       --------  -------  --------  -------  --------  ------- 
 Basic diluted earnings per 
  share                                   1,725     6.9p       538     2.1p     3,404    13.5p 
                                       --------  -------  --------  -------  --------  ------- 
 Adjusted diluted earnings 
  per share                               2,953    11.7p     3,934    15.6p    10,253    40.5p 
                                       --------  -------  --------  -------  --------  ------- 

Adjusted earnings per share before amortisation of acquired intangible assets and adjustments has been shown because, in the opinion of the Directors, it more accurately reflects the trading performance of the Group.

   8.     Dividend 

The Directors have declared an interim dividend of 4.7p per share for the half year ended 31 March 2022 (2021: 4.5p).

                                        Half Year       Half Year       Full Year 
                                            to              to              to 
                                        31 Mar 2021     31 Mar 2021     30 Sep 2021 
                                        (Unaudited)     (Unaudited)      (Audited) 
                                         GBP'000         GBP'000         GBP'000 
                                     --------------  --------------  -------------- 
 Final 2021 dividend paid in 2022: 
  7.7p per share                              1,928               -           1,127 
                                              1,928               -           1,127 
                                     --------------  --------------  -------------- 
   9.     Borrowings 
                     31 March   31 March   30 September 
                       2022       2021         2021 
                      GBP000     GBP000       GBP'000 
                    ---------  ---------  ------------- 
 Bank borrowings           66         64             65 
 Leases                 1,485      1,647          1,588 
                    ---------  ---------  ------------- 
                        1,551      1,711          1,653 
                    ---------  ---------  ------------- 
 Bank borrowings       14,813     19,951         10,903 
 Leases                 4,575      5,684          5,039 
                       19,388     25,635         15,942 
                    ---------  ---------  ------------- 
 Total borrowings      20,939     27,346         17,595 
                    ---------  ---------  ------------- 

G&H's primary lending bank is NatWest Bank. The Group's facilities comprise a $40m (GBP30.4m) dollar revolving credit facility and a $30m (GBP22.8m) flexible acquisition facility. At 31 March 2022, the balance drawn on the revolving credit facility was $19.6m (GBP14.9m) (September 2021: $14.8m (GBP11.0m)) and on the flexible acquisition facility nil (September 2021: nil).

The facilities above are committed until 31 March 2027 and attract an interest rate of between 1.6% and 2.1% above rates specified by the bank dependent upon the Company's leverage ratio, payable on rollover dates.

The Group's banking facilities are secured on certain of its assets including land and buildings, property plant and equipment and inventory.

Maturity profile of bank borrowings

                               31 March   31 March   30 September 
                                 2022       2021         2021 
                                GBP000     GBP000       GBP'000 
 Within one year                     66         64             65 
 Between one and five years      14,813     19,951         10,903 
                                 14,879     20,015         10,968 
                              ---------  ---------  ------------- 

Maturity profile of lease liabilities

                               31 March   31 March   30 September 
                                 2022       2021         2021 
                                GBP000     GBP000       GBP'000 
 Within one year                  1,697      1,921          1,819 
 Between two and five years       3,605      4,616          4,081 
 After five years                 1,505      1,729          1,544 
                              ---------  ---------  ------------- 
                                  6,807      8,266          7,444 
                              ---------  ---------  ------------- 
   10.   Called up share capital 
                               31 Mar 2022    30 Sep 2021    31 Mar 2022   30 Sep 2021 
                                    No.            No.         GBP'000       GBP'000 
 Allotted, issued and fully 
  Ordinary share of 20p 
  each                           25,040,919     25,040,919         5,008         5,008 
                              -------------  -------------  ------------  ------------ 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.



(END) Dow Jones Newswires

June 07, 2022 02:00 ET (06:00 GMT)

Gooch & Housego (LSE:GHH)
Historical Stock Chart
From Sep 2022 to Oct 2022 Click Here for more Gooch & Housego Charts.
Gooch & Housego (LSE:GHH)
Historical Stock Chart
From Oct 2021 to Oct 2022 Click Here for more Gooch & Housego Charts.